Published in Blood on June 03, 2008
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Allele-specific chromatin remodeling in the ZPBP2/GSDMB/ORMDL3 locus associated with the risk of asthma and autoimmune disease. Am J Hum Genet (2009) 2.56
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J (2010) 2.43
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Population genomics in a disease targeted primary cell model. Genome Res (2009) 2.20
Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet (2011) 1.51
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther (2011) 1.43
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics (2009) 1.37
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet (2013) 1.16
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics (2010) 1.14
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
Genetic modulation of horizontal cell number in the mouse retina. Proc Natl Acad Sci U S A (2011) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02
Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther (2009) 1.01
Missing heritability of common diseases and treatments outside the protein-coding exome. Hum Genet (2014) 1.00
Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics (2011) 0.97
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol (2014) 0.97
PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet Genomics (2016) 0.96
Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans. AIDS Res Hum Retroviruses (2012) 0.96
Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med (2009) 0.95
The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. Br J Clin Pharmacol (2013) 0.94
Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol (2013) 0.93
Pharmacogene regulatory elements: from discovery to applications. Genome Med (2012) 0.91
Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol (2009) 0.91
VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey. PLoS One (2010) 0.88
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol (2010) 0.86
Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility. Genome Med (2009) 0.85
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clin Pharmacol Ther (2014) 0.83
Uncovering drug-responsive regulatory elements. Pharmacogenomics (2015) 0.83
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Partitioning transcript variation in Drosophila: abundance, isoforms, and alleles. G3 (Bethesda) (2011) 0.81
Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.80
Warfarin genotyping using three different platforms. Am J Transl Res (2010) 0.80
Screening for 392 polymorphisms in 141 pharmacogenes. Biomed Rep (2014) 0.80
Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand? Pharmacogenomics (2013) 0.79
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol (2012) 0.79
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.78
Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect. Pharmacogenomics (2011) 0.78
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur J Clin Pharmacol (2010) 0.77
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics (2014) 0.77
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet Genomics (2016) 0.76
Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays. Clin Chim Acta (2010) 0.75
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS (2016) 0.75
Allele specific analysis of the ADRBK2 gene in lymphoblastoid cells from bipolar disorder patients. J Psychiatr Res (2009) 0.75
Genes affecting warfarin response-interactive or additive? J Clin Pharmacol (2014) 0.75
Personalized healthcare in clotting disorders. Per Med (2010) 0.75
G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population. Biomed Res Int (2016) 0.75
Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS One (2013) 0.75
Genetics of warfarin sensitivity in an emergency department population with thromboembolic. West J Emerg Med (2011) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
Familial primary antiphospholipid syndrome: A report of co-occurrence in three Malaysian family members. Eur J Rheumatol (2016) 0.75
The Promises of Quantitative Proteomics in Precision Medicine. J Pharm Sci (2016) 0.75
Regulatory Variants Modulate Protein Kinase C α (PRKCA) Gene Expression in Human Heart. Pharm Res (2017) 0.75
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Front Pharmacol (2017) 0.75
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Br J Cancer (2017) 0.75
Translating the histone code. Science (2001) 56.77
Chromatin modifications and their function. Cell (2007) 55.98
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
The role of DNA methylation in mammalian epigenetics. Science (2001) 9.26
Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol (2000) 8.89
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (1997) 7.66
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
Identification of the gene for vitamin K epoxide reductase. Nature (2004) 4.52
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics (2005) 2.68
Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A (2007) 2.62
Evaluation of genetic factors for warfarin dose prediction. Clin Med Res (2007) 2.37
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 2.19
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation (2006) 1.86
Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther (2006) 1.84
Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem (2006) 1.82
Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res (2006) 1.78
In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum Mol Genet (2007) 1.62
The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv (2006) 1.61
A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther (2006) 1.61
Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 1.54
Chromatin immunoprecipitation in postmortem brain. J Neurosci Methods (2006) 1.43
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 1.40
DNA methylation, imprinting and cancer. Eur J Hum Genet (2002) 1.32
Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther (2004) 1.32
The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother (2005) 1.29
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics (2006) 1.27
Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal (2006) 1.16
Population variation in VKORC1 haplotype structure. J Thromb Haemost (2006) 1.05
v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. J Biol Chem (2007) 1.03
The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol (2006) 1.02
The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost (2004) 1.02
Single nucleotide extension technology for quantitative site-specific evaluation of metC/C in GC-rich regions. Nucleic Acids Res (2005) 1.01
Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol (2006) 0.97
Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study. Arterioscler Thromb Vasc Biol (2008) 0.94
Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans. Thromb Haemost (2007) 0.85
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem (2005) 3.53
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol (2005) 3.03
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics (2005) 2.68
Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A (2007) 2.62
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther (2005) 2.20
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80
Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol (2005) 1.73
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet (2011) 1.69
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett (2005) 1.63
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res (2005) 1.58
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 1.54
In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther (2005) 1.54
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics (2005) 1.53
Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques (2003) 1.53
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet (2012) 1.52
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension (2013) 1.52
Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics (2008) 1.51
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens (2015) 1.43
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail (2006) 1.41
Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors. Hum Mol Genet (2006) 1.41
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. Am J Hypertens (2009) 1.40
Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther (2004) 1.32
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther (2003) 1.32
A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis. Genetics (2003) 1.31
Protocols for cytogenetic studies of human embryonic stem cells. Methods (2008) 1.30
Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy (2002) 1.28
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics (2006) 1.27
Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation (2012) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J (2006) 1.24
Sequencing complex diseases With HapMap. Genetics (2004) 1.22
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One (2012) 1.21
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics (2011) 1.20
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol (2006) 1.19
Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism (2011) 1.15
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics (2007) 1.15
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension (2009) 1.15
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension (2013) 1.14
Pharmacogenetics of beta-blockers. Pharmacotherapy (2007) 1.13
Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One (2009) 1.13
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One (2013) 1.10
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics (2012) 1.09
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
Warfarin: an old drug but still interesting. Pharmacotherapy (2008) 1.08
Modeling sequence-sequence interactions for drug response. Bioinformatics (2007) 1.08
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol (2009) 1.08
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.06
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J (2008) 1.05
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther (2005) 1.04
Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy (2004) 1.04
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem (2004) 1.03
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol (2011) 1.03
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation (2013) 1.01
Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis (2010) 0.99
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet (2013) 0.99
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther (2005) 0.99
Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. Pharm Res (2003) 0.99
Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation (2012) 0.97
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med (2012) 0.97
Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy (2014) 0.96
Genetic influence on exercise-induced changes in physical function among mobility-limited older adults. Physiol Genomics (2014) 0.95
Calmodulin binding to peptides derived from the i3 loop of muscarinic receptors. Pharm Res (2006) 0.95
Very important pharmacogene summary ADRB2. Pharmacogenet Genomics (2010) 0.94
Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes. Stem Cell Res (2011) 0.94
Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol (2007) 0.94
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet (2009) 0.94
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens (2013) 0.91
A comparison of students' self-assessments with faculty evaluations of their communication skills. Am J Pharm Educ (2013) 0.91
Genetic variants of the human dipeptide transporter PEPT1. J Pharmacol Exp Ther (2005) 0.91
Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy (2006) 0.91